Will ASML, Lilly, or TransDigm Be the Next Big Stock Split?

Market Context as Splits Return to Focus in 2026

Stock splits have resurfaced as a notable theme in 2026, with several high‑priced names adopting forward splits to broaden ownership. After KLA announced a 10-for-1 forward split in May alongside a solid earnings report and a dividend increase, traders started projecting which megacaps could follow suit. Booking Holdings also pushed a 25-for-1 split earlier in the year, reshaping how the market views shares that once traded well above $4,000.

The chatter now centers on three names that routinely appear in split‑speculation columns: ASML, Lilly, and TransDigm. All trade at lofty nominal prices and boast long, storied charts. None has announced a split yet, but investors are watching for signals from management boards and corporate calendars that could tilt the odds.

The Case for Stock Splits in 2026

Industry observers see several catalysts that could rekindle the stock split playbook. A broad market backdrop marked by volatility, a desire to improve liquidity, and a bid to keep stock prices accessible to smaller investors are among the strongest drivers. In practical terms, splits don’t alter a company’s market cap or fundamentals, but they do change the price per share and, often, the liquidity profile for common investors.

Supporters argue that a split can help with index fund trading, make options trading more attractive, and bring in new ownership groups during a period of capital market normalization. Critics say splits waste capital that could be deployed on buybacks, dividends, or growth initiatives, especially if the underlying business remains robust but the share price simply sits at a high level.

Ranking: Least Likely to Most Likely

Market watchers routinely quantify the odds of a split by weighing company size, price per share, liquidity, and board sentiment. Based on current conditions in May 2026, here is a rough hierarchy for the trio under focus:

• 3. TransDigm (TDG) — Least Likely
  The aerospace components maker trades at a level that, for the moment, hasn’t drawn the same liquidity push as other megacaps. While the company has delivered healthy earnings growth and a strong backlog, a split would be more about market accessibility than immediate investor demand. Analysts note that any decision would hinge on broader capital-allocation priorities and the long-term strategic plan.
• 2. Eli Lilly (LLY) — Medium
  Lilly sits in a sweet spot of high earnings credibility and a wide institutional base, but its product cycle and pipeline risks add complexity. A split could attract more retail buyers without dampening the company’s differentiated growth story, yet management hasn’t signaled urgency. Investors will scan for any hints in communications from the quarterly framework or investor days.
• 1. ASML (ASML) — Most Likely
  The Dutch semiconductor equipment giant often sits at the top of split chatter because of its towering price in many markets and the global willingness to own high-value growth names. If market conditions stay constructive and liquidity themes persist, ASML would be the name most likely to consider a forward split to widen the buyer base and align with peers who have recently split.

What Could Trigger a Split and What It Might Look Like

Several practical triggers could push any of these names toward a split, including a sustained run of earnings strength, a strategic shift toward increased equity liquidity, or a desire to align with a broader investor base in a rising-rate environment. Practical models suggest that a split, particularly a forward split, could be designed to land the price per share in a more 'retail-friendly' range while preserving the market cap and underlying value of the company.

Key considerations include:

• Share price versus liquidity balance: boards tend to favor splits when the price sits well above the typical investor’s comfort zone, but not so high that liquidity wanes.
• Impact on dividends and buybacks: many companies keep dividends steady per share post-split, which can actually improve headline yields despite a lower price per share.
• Market timing and investor sentiment: a split often aligns with favorable funding conditions or strong growth narratives.

Data Snapshot and Market Pulse

The following data points offer a snapshot of where each name sits in late May 2026, acknowledging that prices shift daily and that splits would require board approvals and regulatory clearance.

• ASML: price range tied to European markets, with U.S. listing showing a multi-hundred‑billion market cap footprint and a price per share high enough to attract attention from liquidity-focused funds and cash-heavy portfolios.
• Lilly: large‑cap pharma profile with diversified revenue, a price per share that crosses the comfort line for some retail buyers, and a robust pipeline that supports ongoing investor interest.
• TransDigm: aerospace components specialist with steady cash generation, a more modest market cap by megacap standards, but strong aftermarket demand and a path to consistent earnings growth.

Market conditions in May 2026 show a mixed backdrop: rates hovering near a policy plateau, inflation gradually cooling, and equities trading with a cautious tilt as investors digest earnings and guidance. Against this backdrop, the impulse to adopt a forward stock split among high-priced names remains a live theme for boards and investor teams alike.

Bottom Line: Will ASML, Lilly, or TransDigm Follow the Split Wave?

The central question remains clear: will asml, lilly, transdigm decide to pursue a forward stock split to broaden ownership and potentially boost liquidity? The answer is not imminent for any of the three, but the market is watching every quarterly update and every investor day for a possible signal. If the broader market continues to favor accessibility and liquidity, the likelihood that one of these names will join the split trend increases modestly through the rest of 2026.

For traders and long-term holders alike, the focus should stay on fundamentals, liquidity, and the way a split would fit into a broader capital-allocation strategy rather than on a speculative countdown. The split question, after all, is ultimately about how a company wants to position itself in a market that prizes both growth and tradable liquidity. And as long as will asml, lilly, transdigm remains a live topic, investors will keep a close watch on any official move or formal update from management.